

Abbott Laboratories (Pakistan) Limited

City Office: 8th Floor Faysal House ST-02, Sharah-e-Faisal, Karachi-75350 P.O. Box 7229 Karachi. Tel: +92-21-32799018-19

Abbott Laboratories (Pakistan) Limited

Registered Office: Opp. Radio Pakistan Transmission Centre, Hyderabad Road, Landhi, Karachi-75120 P.O. Box 7229 Karachi 74400 Tel: +92-21-111-Abbott (111-222-688)

April 28, 2025

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building,
Stock Exchange Road
Karachi

BASIC AND DILUTED EARNINGS PER

SHARE (Rs. per share)

Sub: Financial Results for the 1st Quarter ended March 31, 2025

Dear Sir,

We have to inform you that the Board of Directors of our Company in their meeting held on Monday, April 28th, 2025, at 11:30 a.m.virtually at Abbott Laboratories (Pakistan) Limited, considered and approved the financial results of the company as follows:

	Jan-Mar	Jan-Mar		
	2025	2024		
	(Rupees	(Rupees '000)		
SALES-NET				
Local	16,856,488	15,238,729		
Export	489,963	790,199		
	17,346,451	16,028,928		
Cost of Sales	(11,504,545)	(11,578,125)		
GROSS PROFIT	5,841,906	4,450,803		
Selling and distribution expenses	(2,721,303)	(2,397,568)		
Administrative expenses	(303,023)	(268,735)		
Other charges	(321,820)	(177,275)		
Other income	260,099	255,541		
	(3,086,047)	(2,588,037)		
	2,755,859	1,862,766		
Finance costs	(3,947)	(6,661)		
PROFIT BEFORE MINIMUM TAX DIFFERENTIAL, FINAL TAXES AND INCOME TAX	2,751,912	1,856,105		
Minimum tax differential Final taxes	(23,624)	(100,624) (7,902)		
	2,728,288	1,747,579		
TAXATION		200000000		
- Current	(1,207,589)	(164,709)		
- Deferred	78,974	(64,110)		
	(1,128,615)	(228,819)		
NET PROFIT FOR THE PERIOD	1,599,673	1,518,760		

16.34





The Quarterly Report of the Company for the period ended March 31st, 2025 will be transmitted through PUCARS separately, within the specified time.

Yours faithfully,
ABBOTT LABORATORIES (PAKISTAN) LIMITED

SYED ANIS AHMED CHIEF EXECUTIVE & MANAGING DIRECTOR



ABBOTT LABORATORIES (PAKISTAN) LIMITED CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION AS AT MARCH 31, 2025

	Note	March 31, 2025	December 31, 2024 in '000	
	11010	(Un-audited)	(Audited)	
<u>ASSETS</u>				
NON-CURRENT ASSETS				
Property, plant and equipment Intangible assets Long-term loans and advances	6	14,401,709 1,042 116,465	14,252,797 1,250 114,226	
Long-term deposits Long-term prepayments		32,713 12,083	7,513 13,710	
Total Non-current Assets		14,564,012	14,389,496	
CURRENT ASSETS				
Stores and spares Stock-in-trade Trade debts	7	513,915 11,273,874 3,425,879	529,619 10,694,515 2,982,679	
Loans and advances Trade deposits and short-term prepayments Other receivables	8 9	1,401,791 409,023 1,050,254	938,021 283,813 1,182,530	
Taxation - net Cash and bank balances	10	115,604 6,594,125	468,136 6,182,349	
Total Current Assets		24,784,465	23,261,662	
TOTAL ASSETS		39,348,477	37,651,158	
EQUITY AND LIABILITIES SHARE CAPITAL AND RESERVES				
Authorised capital 200,000,000 ordinary shares of Rs.10 each		2,000,000	2,000,000	
Issued, subscribed and paid-up capital Reserves	11	979,003	979,003	
- Capital - Revenue		1,823,757 21,615,822	1,750,481 20,995,152	
		23,439,579	22,745,633	
Total Equity		24,418,582	23,724,636	
NON-CURRENT LIABILITIES Deferred taxation		973,613	1,052,587	
Staff retirement benefits		1,204,951	1,184,179	
Long-term lease liabilities	12	30,699	29,545	
Total Non-current Liabilities		2,209,263	2,266,311	
CURRENT LIABILITIES	4.0		40.054.000	
Trade and other payables Current maturity of lease liabilities	13 12	11,046,993 23,568	10,951,662 22,683	
Unclaimed dividends	12	61,300	63,715	
Unpaid dividend		979,003	-	
Provisions Total Current Liabilities		609,768	622,151	
Total Current Liabilities		12,720,632	11,660,211	
CONTINGENCIES AND COMMITMENTS	14			
TOTAL EQUITY AND LIABILITIES		39,348,477	37,651,158	

The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.

CHIEF EXECUTIVE

DIRECTOR

- Dughan

CHIEF FINANCIAL OFFICER

ABBOTT LABORATORIES (PAKISTAN) LIMITED CONDENSED INTERIM STATEMENT OF CASH FLOWS FOR THE THREE MONTHS ENDED MARCH 31, 2025 (UN-AUDITED)

	Note	March 31, March 31, 2025 2024 Rupees in '000	
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations Income taxes paid Long-term loans and advances - net Long-term deposits - net Long-term prepayments - net Net movement in provisions Net cash inflow / (outflow) from operating activities	17	1,720,598 (878,681) (2,239) (25,200) 1,627 (12,383) 803,722	368,584 (613,901) (4,544) - (688) - (250,549)
CASH FLOWS FROM INVESTING ACTIVITIES		003,722	(200,543)
Additions to property, plant and equipment Sale proceeds from disposal of property, plant and equipment Interest income received Net cash outflow from investing activities		(645,628) 146,084 111,921 (387,623)	(472,497) 24,448 109,037 (339,012)
CASH FLOWS FROM FINANCING ACTIVITIES			
Finance costs paid Dividends paid Net cash outflow from financing activities		(1,908) (2,415) (4,323)	(1,627) (1,029,535) (1,031,162)
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS		411,776	(1,620,723)
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD	4-0	6,182,349	5,036,712
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	17.2	6,594,125	3,415,989

DIRECTOR

The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.

CHIEF EXECUTIVE

CHIEF FINANCIAL OFFICER

ABBOTT LABORATORIES (PAKISTAN) LIMITED CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY FOR THE THREE MONTHS ENDED MARCH 31, 2025

Reserves

	Share	Capital Reserves		Revenue Reserves			
	Capital	Reserve Arising on Merger	Other	General Reserve	Un- appropriated Profit	Total	Total Equity
				Rupees in '0	000		
Balance as at January 1, 2024 (Audited)	979,003	46,097	1,391,065	5,338,422	10,482,759	17,258,343	18,237,346
Transactions with owners, recorded directly in equity							
Employee benefit cost under IFRS 2- 'Share based payments'	-	-	82,484	-	-	82,484	82,484
Total comprehensive income for the period ended March 31, 2024							
Net profit for the period	-	-	-	-	1,518,760	1,518,760	1,518,760
Other comprehensive income for the period	-	-	-	-	-	-	-
	-	-	-	-	1,518,760	1,518,760	1,518,760
Balance as at March 31, 2024 (Un-audited)	979,003	46,097	1,473,549	5,338,422	12,001,519	18,859,587	19,838,590
Balance as at January 01, 2025 (Audited)	979,003	46,097	1,704,384	5,338,422	15,656,730	22,745,633	23,724,636
Transactions with owners, recorded directly in equity Final dividend for the year ended December 31, 2024 @ Rs. 10.0 per share declared subsequent to the year end Employee benefit cost under IFRS 2- 'Share based payments'		- -	- 73,276	-	(979,003) -	(979,003) 73,276	(979,003) 73,276
Total comprehensive income for the period ended March 31, 2025							
Net profit for the period	-	-	-	-	1,599,673	1,599,673	1,599,673
Other comprehensive income for the period	-	-	-	-	-	-	-
	-	-	-	-	1,599,673	1,599,673	1,599,673
Balance as at March 31, 2025 (Un-audited)	979,003	46,097	1,777,660	5,338,422	16,277,400	23,439,579	24,418,582

The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.

CHIEF EXECUTIVE

DIRECTOR

CHIEF FINANCIAL OFFICER